peptides for hair growth
the direct benchmark lane includes minoxidil and oral 5-alpha-reductase inhibitors; copper peptides and RU58841 answer different evidence questions.
minoxidil, finasteride, and dutasteride have direct human alopecia outcomes, with different US indication and formulation boundaries. topical minoxidil and oral finasteride have hair-loss indications; oral minoxidil and dutasteride hair use are off-label in the US. evidence for one route or product does not transfer to another.
copper peptides have follicle biology and smaller clinical files. RU58841 has preclinical and human-scalp-graft signals, but the reviewed record does not contain published human trial results or an established safety margin.
the benchmark drugs, then the copper-peptide record.
minoxidil, finasteride, and dutasteride have human hair outcomes with product and population limits. copper peptides have follicle biology and smaller clinical files.
- ghk-cu (tier S) · copper-binding tripeptide. pickart isolated it from human plasma at ucsf in 1973.
- ahk-cu (tier C) · alanine-histidine-lysine copper tripeptide. characterized in the 1990s extension of pickart's copper-peptide program.
- klow (tier C) · four-peptide compounded blend: kpv, ghk-cu, bpc-157, tb-500.
- glow (tier C) · three-peptide blend: bpc-157, ghk-cu, tb-500.
- Finasteride (tier S) · Finasteride is an oral type-II 5-alpha-reductase inhibitor with an FDA-approved male-pattern-hair-loss indication in men and large randomized hair-count trials.
- Minoxidil (tier S) · Minoxidil has separate evidence lanes: FDA-reviewed topical products for pattern hair loss and an oral tablet labeled for severe hypertension. Oral hair use is off-label.
- Dutasteride (tier A) · Dutasteride inhibits type-I and type-II 5-alpha-reductase. Two randomized oral trials support male androgenetic-alopecia outcomes, but US Avodart approval is for BPH, not hair loss.
different evidence lanes, not benchmark substitutes.
RU58841 has an investigational antiandrogen record. cosmetic peptides and tissue-repair compounds draw from scalp, cell, animal, face-wrinkle, or adjacent biology that does not equal an approved hair-regrowth indication.
- snap-8 (acetyl-octapeptide-3) (tier D) · lipotec acetyl-octapeptide-3. a snap-25 c-terminal mimic that competes with snare-complex assembly to reduce facial-muscle contraction.
- bpc-157 (tier C) · gastric-juice protection fragment with rodent tendon, vascular, and gut-healing data.
- tb-500 (tier C) · 7-amino-acid lkktetq fragment of thymosin-β4.
- RU58841 (tier C) · RU58841 is a topical nonsteroidal androgen-receptor antagonist research chemical with macaque and human-scalp-graft signals, plus two completed human-study registrations without published results.
specific-question reference.
is any peptide fda-approved for hair regrowth?
no peptide on this page has an fda hair-regrowth indication. topical minoxidil and oral finasteride have US hair-loss indications; oral minoxidil and dutasteride hair use are off-label in the US. RU58841 remains investigational. none of those records validates a compounded topical or another route.
how does ghk-cu compare to minoxidil?
the 2023 chinese mouse study with an ionic-liquid microemulsion vehicle reported earlier anagen entry for topical ghk-cu (6 days) than 5% minoxidil (9 days). that is one preclinical model with engineered delivery. the published human comparison literature is small-n and inconclusive. minoxidil has the long-form efficacy and safety record.
is ahk-cu the same as ghk-cu?
no. both are copper tripeptides from pickart's program. ghk has 50 years of cosmetic and mechanistic literature including the 2014 connectivity-map paper (4,192 genes). ahk-cu has narrower, mostly cosmetic-industry data and one notable 120% dermal-papilla proliferation in vitro reading. they are not evidence-interchangeable.
do glow and klow prove hair regrowth?
no. blend-specific hair-density rcts do not exist. the rationale runs through the ghk-cu component plus general tissue-remodeling extrapolation. that is clinic formulation logic, not phase-3 evidence.
is snap-8 a hair peptide?
no. snap-8 is acetyl-octapeptide-3, a snap-25 c-terminal mimic developed by lipotec for face-wrinkle products. the 63% wrinkle-depth reduction in the sponsor study is at 10% topical on face. scalp use is marketing extension without controlled data.
do bpc-157 or tb-500 belong in a hair-regrowth map?
no. they can be relevant to post-transplant healing because that is a wound question. tendon and vascular biology in rats is not evidence for de novo follicle regrowth in humans.
what the safety literature reports.
what does the topical ghk-cu safety record look like?
ghk-cu has 40+ years of cosmetic use without an adverse-event signal worth tabling. local irritation and contact dermatitis are reported at the same rate as inactive vehicle in pickart-era literature. the safety story is the strongest part of the cosmetic copper-peptide case.
what happens when copper peptides go systemic?
injectable ghk-cu and ahk-cu have a thinner human evidence base than the topical. the cosmetic safety record does not carry across to systemic dosing. no controlled long-term injectable trial in healthy adults.
what is the biggest evidence gap in the category?
controlled human hair-density outcomes for any peptide formula. mouse models and in vitro dermal-papilla work exist. minoxidil-arm controlled human rcts do not.
claim checks
related comparisons
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.